rs2050122 — HTR6

Regulatory variant near the HTR6 serotonin 6 receptor gene associated with chronotype; the minor T allele is linked to reduced morningness and a modest shift toward evening preference.

See your personal result for HTR6

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

HTR6 and Chronotype — Serotonin's Quiet Hand on Your Body Clock

The serotonin 6 receptor11 serotonin 6 receptor
5-HT6R, encoded by the HTR6 gene on chromosome 1p36.13. A G protein-coupled receptor that signals via adenylate cyclase/cAMP and is expressed primarily in striatal and cortical neurons is best known in pharmacology for being inadvertently blocked by most antipsychotics and several antidepressants. But rs2050122, a variant in the regulatory region flanking HTR6, has now emerged from large-scale genome-wide association studies as a bona fide signal for chronotype — the internal timing preference that sorts people into larks and owls.

The T allele at rs2050122 is the minor allele globally (~25%) and in Europeans (~22%), while the common C allele predominates in most ancestries. GWAS data from three independent chronotype studies consistently find that the C allele is modestly associated with morning preference, meaning T-allele carriers — particularly TT homozygotes — show a slight but statistically robust shift toward eveningness.

The Mechanism

HTR6 is expressed in neurons of the striatum and frontal cortex22 striatum and frontal cortex
The striatum is the primary site of HTR6 expression; high receptor density has also been reported in the olfactory tubercle, hippocampus, and motor nuclei, where it exerts tonic inhibitory control over glutamate and acetylcholine release via Gs-mediated cAMP elevation. When 5-HT6 receptors are blocked pharmacologically, extracellular glutamate in the frontal cortex rises two- to three-fold — a finding that explains why 5-HT6 antagonists are being developed as pro-cognitive agents.

The rs2050122 variant lies in the regulatory region near HTR6. While its precise molecular effect on HTR6 expression has not been characterized at the mechanistic level, the GWAS signal maps the variant to HTR6 in multiple independent datasets. The leading biological hypothesis is that altered HTR6 expression changes serotonergic tone in the suprachiasmatic nucleus (SCN)33 suprachiasmatic nucleus (SCN)
The master pacemaker of the circadian clock in the hypothalamus, receiving direct photic input from the retina and relaying timing information to peripheral clocks throughout the body and its downstream targets, modulating the phase or amplitude of circadian output. Serotonin is a well-established modulator of the SCN clock — it shifts the phase of SCN firing rhythms both in vitro and in vivo — but the specific HTR6 contribution to this effect is an active area of investigation.

The Evidence

Three independent chronotype GWAS studies have implicated rs2050122:

Lane et al. 201644 Lane et al. 2016
Lane JM et al. Genome-wide association analysis identifies novel loci for chronotype in 100,420 individuals from the UK Biobank. Nature Communications, 2016 was the first large-scale study to report this locus. Chronotype was assessed via self-reported morning/evening preference in over 100,000 UK Biobank participants.

Jones et al. 201655 Jones et al. 2016
Jones SE et al. Genome-Wide Association Analyses in 128,266 Individuals Identifies New Morningness and Sleep Duration Loci. PLoS Genetics, 2016 replicated the association in 128,266 individuals combining UK Biobank and 23andMe cohorts.

The definitive study is the expanded chronotype GWAS by Jones et al. 201966 Jones et al. 2019
Jones SE et al. Genome-wide association analyses of chronotype in 697,828 individuals provides insights into circadian rhythms. Nature Communications, 2019 in nearly 700,000 individuals, which identified 351 chronotype loci and confirmed rs2050122 as a genome-wide significant signal (beta=0.031 for morningness, p=5×10⁻⁸). The per-allele effect size of ~0.031 on a normalized morningness scale translates to roughly 3–5 minutes of earlier habitual sleep timing per C allele. This is a modest individual effect, as expected for a polygenic trait, but the signal is robustly replicated.

The enrichment of chronotype GWAS hits in glutamate signaling, cAMP pathways, and brain regions co-expressing circadian and serotonin machinery is consistent with the biological plausibility of HTR6's involvement in timing.

Practical Actions

The effect size at this single locus is small — roughly 3–5 minutes of chronotype shift per allele — and TT homozygotes carry only a subtle predisposition toward eveningness. However, the T allele matters most when it compounds with other eveningness-associated variants across the genome. People with TT genotype at rs2050122 who also carry evening-associated alleles at PER2, CLOCK, or CRY1 loci may experience a more pronounced owl phenotype.

For TT carriers who report difficulty waking early, light exposure in the morning — particularly bright light therapy77 bright light therapy
10,000 lux for 20–30 minutes within one hour of waking, the intervention studied most rigorously for chronotype shifting — is the most evidence-based behavioral intervention for phase-advancing the circadian clock, regardless of genetic cause.

Interactions

rs2050122 acts within the broader polygenic architecture of chronotype. Its effect is additive with other chronotype variants. The most studied clock gene SNPs in the GeneOps database include PER3 rs10462020 (V647G, morningness-associated under a recessive model), PER3 rs228697 (Pro864Ala), and CLOCK rs1801260 (eveningness-associated G allele). Individuals carrying the T allele at rs2050122 alongside eveningness alleles at CLOCK or PER2 may show a meaningfully earlier chronotype shift than any single variant predicts in isolation.

The pharmacological intersection is also relevant: SSRIs and many antipsychotics bind HTR6 with moderate affinity. Patients on these medications who notice disrupted sleep timing may be experiencing partial 5-HT6 modulation as a side effect. This is a gene-drug interaction worth discussing with a prescriber, particularly for TT homozygotes where background HTR6 activity may already be altered by the regulatory variant.

Genotype Interpretations

What each possible genotype means for this variant.

CC Common Chronotype Normal

Common allele homozygote — no predisposition toward evening preference at this locus

The C allele is associated with slightly increased morningness in GWAS data from nearly 700,000 individuals (beta=0.031 per allele, Jones et al. 2019). As a CC homozygote, you have the maximum morningness contribution at this locus — though the absolute effect is modest (approximately 5–7 minutes of sleep timing difference relative to TT carriers). Chronotype is highly polygenic; your overall morning vs. evening preference depends on hundreds of loci, not this one alone.

CT Mixed Chronotype Signal Intermediate

One T allele — minor shift toward evening preference

GWAS data place the per-allele beta at ~0.031 on a normalized morningness scale (Jones et al. 2019). For CT heterozygotes, this translates to a roughly 3–4 minute shift toward evening preference relative to CC carriers. This is not clinically meaningful as an isolated finding but becomes more relevant when combined with evening-associated alleles at CLOCK, PER2, CRY1, or other chronotype loci.

The T allele is thought to influence HTR6 regulatory activity, potentially reducing serotonergic modulation of circadian pacemaker neurons, but the precise molecular consequence has not been characterized in functional studies.

TT Evening Lean Decreased

Two T alleles — modest but consistent evening chronotype signal

The Jones et al. 2019 chronotype GWAS (N=697,828) identified rs2050122 at genome-wide significance (p=5×10⁻⁸, beta=0.031 per C allele for morningness). As a TT homozygote, you carry zero C alleles at this locus, placing you at the lower end of the morningness distribution attributable to this SNP.

The T allele is the GRCh38 reference allele but is the population-minor allele in Europeans (~22%) and globally (~25%). Its prevalence varies substantially by ancestry — it reaches 95% in East Asian populations and approaches 100% in some Latin American cohorts, where chronotype associations may differ from European findings.

From a pharmacological perspective, drugs that interact with HTR6 — including clozapine, olanzapine, and several SSRIs — may have differential chronotype effects in TT carriers if the regulatory variant alters baseline HTR6 expression. This has not been directly studied but is consistent with the broader literature on serotonergic modulation of circadian timing.